Flaxseed lignan complex and its use thereof

• US 10,045,951 B2
• Filed: 04/11/2011
• Issued: 08/14/2018
• Est. Priority Date: 05/25/2007
• Status: Active Grant

• Current Assignee: Trustees Of The University Of Pennsylvania (University of Pennsylvania)
• Original Assignee: Trustees Of The University Of Pennsylvania (University of Pennsylvania)
• Inventors: Christofidou-Solomidou, Melpo
• Primary Examiner(s): CLARK, AMY LYNN
• Application Number:
  US13/084,408
• Publication Number:
  US 20110300247A1
• Time in Patent Office: 2,682 Days
• Field of Search: None
• CPC Class Codes: A61K 31/065 Diphenyl-substituted acyclic alcohols
• CPC Class Codes: A61K 31/365 Lactones
• CPC Class Codes: A61K 31/7032 attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
• CPC Class Codes: A61K 36/55 Linaceae (Flax family), e.g. Linum
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system

Abstract

The invention relates compositions and methods for treating pathological lung conditions using whole-grain flaxseed or flaxseed lignans. Specifically, the invention relates to the dietary use of flaxseed lignans.

Claims

1. A method for therapeutically treating a radiation-induced lung disease in a subject in need thereof, the method comprising:

administering to said subject a therapeutically effective amount of at least one purified or chemically synthesized lignan, thereby treating said radiation-induced lung disease in said subject, wherein said lignan is selected from secoisolariciresinol diglucoside (SDG), enterodiol (ED), enterolactone (EL), or a combination thereof.

2. The method of claim 1, wherein said radiation-induced lung disease is pulmonary fibrosis.

3. The method of claim 1, wherein said subject is an individual exposed to inhaled radioisotope or incidental or accidental radiation.

7. The method of claim 1, wherein, subsequent to administering to said subject said therapeutically effective amount of said at least one lignin, said method further comprises increasing the circulating plasma level of a lignan metabolite in said subject.

8. The method of claim 1, wherein said radiation-induced lung disease is radiation pneumonitis.

4. A method for therapeutically treating radiation-induced pneumonopathy in a subject, the method comprising:

administering to a subject having a radiation-induced pneumonopathy a therapeutically effective amount of at least one purified or chemically synthesized lignan, thereby treating said radiation-induced pneumonopathy in said subject, wherein said lignan is selected from secoisolariciresinol diglucoside (SDG), enterodiol (ED), enterolactone (EL), or a combination thereof.

5. A method for therapeutically treating radiation pneumonitis in a subject, the method comprising:

administering to a subject having radiation pneumonitis a therapeutically effective amount of at least one purified or chemically synthesized lignan, thereby treating said radiation pneumonitis in said subject, wherein said lignan is selected from secoisolariciresinol diglucoside (SDG), enterodiol (ED), enterolactone (EL), or a combination thereof.

6. A method for improving survival of a subject having a radiation-induced lung disease, said subject exposed to an inhaled radioisotope or incidental radiation, the method comprising:

administering to said subject a therapeutically effective amount at least one purified or chemically synthesized lignan, thereby improving survival of said subject, wherein said lignan is selected from secoisolariciresinol diglucoside (SDG), enterodiol (ED), enterolactone (EL), or a combination thereof.